HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate.

Abstract
A 14-year-old girl with juvenile dermatomyositis developed extensive and debilitating calcinosis, unresponsive to colchicine, while muscle involvement subsided. Pamidronate (2mg/kg/year) produced dramatic improvement of pain and function within 2 months and calcinosis had completely resolved by 2 years. No new calcifications have been noted with a 5-year follow-up.
AuthorsSamy Slimani, Amina Abdessemed, Assia Haddouche, Aicha Ladjouze-Rezig
JournalJoint bone spine (Joint Bone Spine) Vol. 77 Issue 1 Pg. 70-2 (Jan 2010) ISSN: 1778-7254 [Electronic] France
PMID20031471 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 2009 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Cholecalciferol
  • Pamidronate
  • Calcium
  • Methylprednisolone
Topics
  • Adolescent
  • Bone Density Conservation Agents (therapeutic use)
  • Calcinosis (diagnostic imaging, drug therapy, etiology)
  • Calcium (administration & dosage)
  • Cholecalciferol (administration & dosage)
  • Dermatomyositis (complications, diagnostic imaging, drug therapy)
  • Diphosphonates (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Methylprednisolone (therapeutic use)
  • Pamidronate
  • Radiography
  • Recovery of Function
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: